Last reviewed · How we verify

TransCon PTH — Competitive Intelligence Brief

TransCon PTH (TransCon PTH) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PTH analogue. Area: Bone disorders.

phase 3 PTH analogue PTH receptor Bone disorders Small molecule Live · refreshed every 30 min

Target snapshot

TransCon PTH (TransCon PTH) — Visen Pharmaceuticals (Shanghai) Co., Ltd.. TransCon PTH is a long-acting parathyroid hormone analogue designed to mimic the natural physiological profile of endogenous parathyroid hormone.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TransCon PTH TARGET TransCon PTH Visen Pharmaceuticals (Shanghai) Co., Ltd. phase 3 PTH analogue PTH receptor
PTH/Calcium PTH/Calcium Shire phase 3 Hormone replacement / Mineral supplement combination PTH receptor (PTH1R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PTH analogue class)

  1. Visen Pharmaceuticals (Shanghai) Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TransCon PTH — Competitive Intelligence Brief. https://druglandscape.com/ci/transcon-pth. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: